← Back to patent-cliff list
CAS 2112-22-3
2,3-dichloro-6-nitrobenzonitrile
Codes: ANAG-008
Application context (from source-drug indications)
Essential thrombocythaemiaAnagrelide Hydrochloride HydrateMyeloproliferative neoplasmAnagrelide Hydrochloride Hydrate血小板增多Anagrelide Hydrochloride HydrateMyelofibrosisAnagrelide Hydrochloride HydrateChronic myeloid leukaemiaAnagrelide Hydrochloride HydratePolycythaemia veraAnagrelide Hydrochloride Hydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Anagrelide Hydrochloride Hydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1,2,3-trichlorobenzene→1,2,3-trichlorobenzene→2,3-dichloro-6-nitrobenzonitrile→(2,3-dichloro-6-nitrophenyl)methanamine→ethyl 2-bromoacetate→ethyl 2-((2,3-dichloro-6-nitrobenzyl)amino)acetate→ethyl 2-((6-amino-2,3-dichlorobenzyl)amino)acetate→6,7-dichloro-3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one hydrobromide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.